Dr. Reddy's Laboratories Limited has informed the Exchange about disclosure Under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Reddy's Laboratories has invested Rs. 565,40,77,993 (approximately Rs. 565.4 Crores) in its step-down wholly-owned subsidiary Dr. Reddy's Laboratories LLC, Russia (DRL Russia), acquiring a 45.19% equity stake. This follows the board's earlier approval (November 5, 2024) for a fund infusion of up to Rs. 600 Crores. The money will be used for the working capital needs of DRL Russia, which distributes pharmaceutical medicines in Russia and posted a turnover of Rs. 2,347 Crores in FY2025, up from Rs. 2,084 Crores in FY2024 and Rs. 1,915 Crores in FY2023. The transaction was done through cash consideration and qualifies as a related party transaction since DRL Russia is a subsidiary.
This is an internal capital infusion into the company's own Russian subsidiary and is unlikely to materially impact the share price. It signals continued operational commitment to the Russian market, which has been a growing revenue contributor for Dr. Reddy's over the past three years.